• 23RD FEBRUARY 2024

    Negotiations on 2024/25 Contractual Framework Commence

    Formal tripartite negotiations on the arrangements for the Community Pharmacy Contractual Framework (CPCF) in 2024/25 – the first year following the five-year CPCF deal – have now begun. The negotiations are taking place between Community Pharmacy England and the Department of Health and Social Care (DHSC), supported by NHS England (NHSE). They are beginning ahead

    Read more
    • 23RD FEBRUARY 2024

    February 2024 Price Concessions 3rd Update

    Following discussions between Community Pharmacy England and the Department of Health and Social Care (DHSC) regarding medicine pricing issues reported by pharmacy owners, the Department has today (23/02/2024) announced the following list of price concessions for February 2024. Please note: We are still in discussion with DHSC on a number other medicines affected by pricing

    Read more
    • 21ST FEBRUARY 2024

    Mounjaro® (Tirzepatide) KwikPen® – availability and reimbursement

    Eli Lilly and Company Ltd has recently launched Mounjaro® (tirzepatide), a new diabetes drug which is also indicated for the treatment of weight loss. Mounjaro® comes in a KwikPen® or auto-injector pre-filled injection pen containing 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg and 15mg of tirzepatide. Currently, only the 2.5mg and 5mg strengths of the KwikPen® are

    Read more
    • 21ST FEBRUARY 2024

    Medicine Supply Notification: Epilim® (sodium valproate) syrup 200mg/5ml

    Department of Health and Social Care (DHSC) has issued a medicine supply notification for Epilim® (sodium valproate) syrup 200mg/5ml MSN/2024/023 Tier 2 – medium impact Date of issue: 21st February 2024 Epilim® 200mg/5ml syrup is out of stock from mid-March until w/c 22nd April 2024. Epilim® (sodium valproate) 200mg/5ml liquid (sugar-free) remains available and can

    Read more
    • 20TH FEBRUARY 2024

    MHRA Drug Safety Update: February 2024

    A new Medicines and Healthcare products Regulatory Agency (MHRA) Drug Safety Update (Vol 17 Issue 7 February 2024) has been published and includes articles on: Codeine linctus (codeine oral solutions): reclassification to prescription-only medicine Pseudoephedrine: very rare risk of posterior reversible encephalopathy syndrome (PRES) and reversible cerebral vasoconstriction syndrome (RCVS) Letters and medicine recalls sent

    Read more